Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.

The article discusses a clinical trial, NCT06655233, focusing on using endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) to study the intratumoral microbiome in patients with pancreatic ductal adenocarcinoma (PDAC) and its impact on tumor diagnosis and prognosis. The study aims to determine if EUS-FNB can accurately detect the microbiome within PDAC tumors and identify specific microbes or metabolites linked to patient prognosis or response to chemotherapy. Participants will be PDAC patients undergoing EUS-FNB, with researchers comparing microbiome data from EUS-FNB samples with surgical biopsies to validate the method's accuracy. The study utilizes 2bRAD-M metagenomic sequencing technology to analyze microbial components and metabolites for early detection and effective treatment strategies for PDAC patients. [Extracted from the article]